Alzheimer’s disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the ‘Aβ hypothesis’, there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.

阿尔茨海默病 (AD) 是最普遍的慢性神经退行性疾病。目前批准的疗法是对认知功能有一定影响的对症疗法。针对 β-淀粉样蛋白 (Aβ) 的疗法一直是开发 AD 疾病改善疗法的重点，但这些方法迄今未能显示出任何临床益处。除了“Aβ 假说”之外，还有许多新的方法来治疗伴有神经炎症的 AD，这些方法正在成为基于风险基因分析的非常活跃的研究领域。这篇简短的综述将总结批准的药物疗法、最近的临床试验和治疗 AD 的新方法。